Home › Funds › O'Connor Alternative Investments LLC › RNA
O'Connor Alternative Investments LLC position in RNA
ATRIUM THERAPEUTICS INC · Health Care
O'Connor Alternative Investments LLC reported holding 559,142 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$4.6M, representing 0.27% of its reported portfolio and ranking #47 among its reported holdings. O'Connor Alternative Investments LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How O'Connor Alternative Investments LLC's RNA position evolved
O'Connor Alternative Investments LLC first disclosed a stake in RNA in Q1 2026 at 578,011 shares (US$7.7M). The position peaked in Q2 2026 at 597,018 shares, worth US$8.0M. Across 3 filings, O'Connor Alternative Investments LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 559,142 shares valued at US$4.6M — a reduction of -37,876 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 578.01K | $7.73M | New |
| Q2 2026 | 597.02K | $8.03M | Add |
| Q3 2026 | 559.14K | $4.63M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNA and 13F data
RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 88 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), TIG Advisors, LLC (US$7.6M), Bracebridge Capital, LLC (US$4.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RNA
- Sessa Capital IM, L.P. 1.50M sh · $20.18M · Q2 2026
- TIG Advisors, LLC 561.53K sh · $7.55M · Q2 2026
- Bracebridge Capital, LLC 524.48K sh · $4.34M · Q3 2026
- Arbiter Partners Capital Management LLC 311.72K sh · $2.58M · Q3 2026
- NEXPOINT ASSET MANAGEMENT, L.P. 150.03K sh · $2.02M · Q2 2026
- Kalehua Capital Management LLC 112.65K sh · $932.76K · Q3 2026
- Athos Capital Ltd 107.97K sh · $894.00K · Q3 2026
- Marble Bar Asset Management LLP 103.90K sh · $860.27K · Q3 2026
- Trium Capital LLP 58.38K sh · $483.40K · Q3 2026
- ALETHEA CAPITAL MANAGEMENT, LLC 43.76K sh · $362.32K · Q3 2026
- Slotnik Capital, LLC 39.93K sh · $330.62K · Q3 2026
- Fortress Investment Group LLC 20.00K sh · $165.60K · Q3 2026
More on O'Connor Alternative Investments LLC
FAQ
How long has O'Connor Alternative Investments LLC held RNA?
O'Connor Alternative Investments LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is O'Connor Alternative Investments LLC's current position in RNA?
As of Q3 2026, O'Connor Alternative Investments LLC holds 559.14K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $4.63M, representing 0.27% of its reported portfolio and ranking #47.
Has O'Connor Alternative Investments LLC been buying or selling RNA?
In the latest 13F filing (Q3 2026), O'Connor Alternative Investments LLC reduced its position in RNA. The position peaked in Q2 2026 at 597.02K shares.
Which other funds hold RNA?
Other major institutional holders of RNA include Sessa Capital IM, L.P., TIG Advisors, LLC, Bracebridge Capital, LLC, among 88 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.